SEC Form 4 · accession 0001179110-17-010236
Nabriva Therapeutics Legacy plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Jul 5, 2017
Accepted (ET)
Jul 7, 2017 · 9:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001703287
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jul 5, 2017 | S | 2,562 | $10.5232 | D | 2,569,315 | D | |
| Ordinary SharesF1 | Jul 7, 2017 | S | 133 | $10.50 | D | 2,569,182 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 23, 2017, Nabriva Therapeutics plc ("Nabriva plc") became the successor of Nabriva Therapeutics AG ("Nabriva AG") pursuant to an exchange offer. Pursuant to the exchange offer, each outstanding common share of Nabriva AG was exchanged for ten ordinary shares of Nabriva plc and each outstanding American Depositary Share of Nabriva AG, which represented one-tenth of one common share of Nabriva AG, was exchanged for one ordinary share of Nabriva plc. On prior reports filed by the reporting person subsequent to the completion of the exchange offer, all references to American Depositary Shares of Nabriva AG should be understood to refer to ordinary shares of Nabriva plc..
- F2The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $10.50 to $10.74 Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price.